Skip to main content

Table 1 Patient characteristics

From: Chemoradiotherapy versus chemotherapy as adjuvant treatment for localized gastric cancer: a propensity score-matched analysis

  Chemoradiation
(N = 227)
Chemotherapy
(N = 82)
P
Age at diagnosis – years    0.124
 Median 58.71 56.51  
 Range 30 - 80 34 - 75  
Sex - No. (%)    0.964
 Male 135 (59.5) 49 (59.8)  
 Female 92 (40.5) 33 (40.2)  
ECOG Performance status - No. (%)    0.401
 0 97 (42.7) 38 (46)  
 1 112 (49.3) 38 (46.3)  
 2 18 (7.9) 5 (6.1)  
 3 0 (0.0) 1 (1.2)  
Histology - No. (%)    0.712
 Diffuse/signet ring 97 (42.7) 34 (41.5)  
 Tubular/intestinal 90 (39.6) 35 (42.7)  
 Not specified 40 (17.6) 13 (15.9)  
TNM Stage group - No. (%)    0.021
 IB 11 (4.8) 3 (3.7)  
 IIA 54 (23.8) 10 (12.2)  
 IIB 43 (18.9) 13 (15.9)  
 IIIA 41 (18.1) 10 (12.2)  
 IIIB 42 (18.5) 22 (26.8)  
 IIIC 36 (15.9) 24 (29.3)  
Lymph node dissection - No. (%)    0.273
 D1 61 (26.9) 17 (20.7)  
 D2 166 (73.1) 65 (79.3)  
Surgical margin - No. (%)    0.359
 R0 207 (91.2) 72 (87.8)  
 R1 18 (7.9) 10 (12.2)  
 R2 2 (0.9) 0 (0.0)